---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Generic, brand name and therapeutic class of product"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Generic, brand name and therapeutic class of product. Topics: Manufacturer: Alumis; Nonproprietary name, former development code, and therapeutic class; Substance names and development codes in the FDA substance registration record; Development code FTP-637 in the first-in-human registry record; 1 further topic. 5 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/generic-brand-name-and-therapeutic-class-of-product"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Generic, brand name and therapeutic class of product

<a id="heading-2.1.2.1"></a>

## 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

### Manufacturer: Alumis

> “Alumis has reported positive results from its Phase 3 ONWARD program of envudeucitinib in moderate-to-severe plaque psoriasis and plans to file an NDA in moderate-to-severe plaque psoriasis in the fourth quarter of 2026.”

Source: [Alumis press release, LUMUS topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926104145/tm2624540d1_ex99-1.htm)

<a id="topic-2.1.2.1-2"></a>

### Nonproprietary name, former development code, and therapeutic class

> “We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (“TYK2”) inhibitors: envudeucitinib (“envu”), formerly known as ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (“CNS”) penetrant allosteric TYK2 inhibitor.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

<a id="topic-2.1.2.1-3"></a>

### Substance names and development codes in the FDA substance registration record

| Field | Quoted record |
| --- | --- |
| Preferred substance name | “ENVUDEUCITINIB” |
| International Nonproprietary Name synonym | “envudeucitinib [INN]” |
| Development code synonym | “ESK-001” |
| Second development code synonym | “FTP-637” |
| Systematic chemical name synonym | “N-[4-[2-methoxy-3-[1-(trideuteriomethyl)-1,2,4-triazol-3-yl]anilino]-5-(3,3,3-trideuteriopropanoyl)-2-pyridinyl]cyclopropanecarboxamide” |

Source: [FDA UNII record for envudeucitinib](https://precision.fda.gov/uniisearch/srs/unii/KD2MDJ4GAB)

<a id="topic-2.1.2.1-4"></a>

### Development code FTP-637 in the first-in-human registry record

| Field | Quoted record |
| --- | --- |
| Public title | “A 2-part, randomised, double-blind, placebo-controlled study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of FTP 637 in healthy volunteers.” |
| Primary sponsor name | “Alumis Inc (formerly Esker Therapeutics, Inc)” |

Source: [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885)

<a id="topic-2.1.2.1-5"></a>

### Company names and acquisition of envudeucitinib

> “Alumis was incubated by Foresite Labs and incorporated on January 29, 2021, as a Delaware corporation under the name FL2021-001, Inc. FL2021-001, Inc.’s name was changed to Esker Therapeutics, Inc. in March 2021, and to Alumis Inc. in January 2022.”
> “For example, we were founded in January 2021, and subsequently acquired envu via a stock purchase of FronThera U.S. Holdings, Inc. and its wholly owned subsidiary, FronThera U.S. Pharmaceuticals LLC.”
> “On March 5, 2021, we entered into the FronThera Acquisition, and the transaction was accounted for as an asset acquisition.”
> “Additionally, we consummated the ACELYRIN Merger in May 2025 and acquired lonigutamab.”

Source: [Alumis Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000006/alms-20251231x10k.htm)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
